Pharmaceutical Industry Lupin Inks Strategic Joint Venture Agreement with Yoshindo

Editor: Dominik Stephan

Lupin has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo to create a new entity, YL Biologics (YLB).

Related Companies

Lupin Inks Strategic Joint Venture Agreement with Yoshindo
Lupin Inks Strategic Joint Venture Agreement with Yoshindo
(Picture: PROCESS)

Mumbai/India – YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain Biosimilars including regulatory filings and obtaining marketing authorizations in Japan.

The new entity YLB will in-license Monoclonal Antibodies (mAbs) from Lupin and also partner with other companies across the globe for the Japanese market which already has a clear cut regulatory regime in place for the development and commercialization of Biologicals. Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical development to YLB. Etanercept (Originator Trade name: Enbrel) is a biopharmaceutical product approved globally for treating autoimmune diseases such as Rheumatoid arthritis, Psoriasis and Ankylosing spondylitis. Enbrel is marketed in Japan by Takeda Pharmaceutical and had sales of USD 496 million.

Commenting on the Joint Venture Dr. Kamal K Sharma, Vice Chairman, Lupin Ltd said, "We are very excited about the joint venture with Yoshindo, a partner who shares our commitment to bringing biosimilars to market in Japan. YLB is a reflection of Lupin's long-term commitment to the Japanese market and is an important first step forward to establishing Lupin's global Biosimilar portfolio."